Tactile Systems Technology (TCMD) Q2 FY26 earnings call

Tactile Medical delivered a strong second quarter, driven by robust performance in its lymphedema business and significant profitability expansion. While the airway clearance segment faced temporary headwinds from DME inventory adjustments related to a new product launch, the company reaffirmed its full-year adjusted EBITDA guidance. Strategic initiatives, including an expanded distribution agreement and LymphaTech's FDA submission, aim to broaden treatment options and improve patient access, positioning the company for sustainable long-term growth.